Clinical Trials Logo

Solitary Pulmonary Nodule clinical trials

View clinical trials related to Solitary Pulmonary Nodule.

Filter by:

NCT ID: NCT01149187 Recruiting - Clinical trials for Solitary Pulmonary Nodule

Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules

Start date: June 2010
Phase: N/A
Study type: Observational

Among the causes of the solitary pulmonary nodule (SPN), benign causes including tuberculosis was noted on 15 to 60 percents in various studies. Although the characteristics of chest imaging is helpful in diagnosis and percutaneous needle biopsy for pulmonary nodule has been represented high diagnostic yield in many reports, but still surgical biopsy has been needed in definite diagnosis of pulmonary nodules in many cases. The aim of this study is to evaluate the usefulness of interferon-gamma release assay in addition to the percutaneous needle biopsy, in diagnosis of pulmonary nodules.

NCT ID: NCT00841750 Recruiting - Clinical trials for Lung Diseases, Interstitial

Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection

NOTUBE
Start date: July 2008
Phase: Phase 3
Study type: Interventional

After performing VATS pulmonary wedge resections, a chest tube is routinely left in the pleural cavity to drain possible air leaks and fluid accumulations. Chest tubes after VATS pulmonary wedge resections are left in place a minimum of 1 day. However, this practice has no scientific foundations. The investigators believe it is possible to avoid the placement of a chest tube after this procedure in a great amount of patients. This is a randomized controlled clinical trial with analysis blinding in which the investigators want to compare the outcomes between installing a chest tube or not after VATS pulmonary wedge resections. The investigators will include consecutively patients with interstitial lung disease or indeterminate pulmonary nodules undergoing this procedure, at the participating institutions. The investigators calculated a sample size of 50 subjects in each group using pneumothorax < 10% data from Luckraz et al and to determine a difference of hospital stay of 2 versus 1 day; DS(1.5), power = 0.9 and alpha = 0.05.